Regeneron acquires Checkmate for $250M, collaborates with SpringWorks on multiple myeloma therapy

A few days ago, Regeneron announced the acquisition of Checkmate Pharmaceuticals, and also said that it will cooperate with SpringWorks Therapeutics on a clinical trial to jointly evaluate the efficacy of Regeneron REGN5458 in combination with SpringWorks drug nirogacestat in patients with multiple myeloma

In terms of acquisitions, Regeneron is expected to acquire Checkmate Pharmaceuticals and its subsidiary Vidutolimod, an investigational immune activator, for about $250 million

It is reported that Vidutolimod is a CpG-A oligodeoxynucleotide Toll-like receptor 9 agonist, and the drug is delivered to the patient's body in the form of virus-like particles

In terms of clinical trial cooperation, Regeneron also said it is collaborating with SpringWorks Therapeutics to conduct a clinical trial to evaluate the therapeutic effect of REGEN5458 in combination with nirogacestat

It is understood that nirogacestat is an investigational, oral, selective small molecule gamma-secretase inhibitor in Phase III clinical development trials for noncancerous growths in desmoid tumors that occur in connective tissue

In Phase I clinical trial results, REGN5458 showed a 75% response rate at the highest dose level, with 83% of patients showing a good partial response

Original English text: https:// href="https://" target="_blank">https://